Loading
Dyadic International Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Aug 2025.
Dyadic International Inc: what insiders have been doing
Every trade that managers of Dyadic International Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 9 insiders have disclosed 18 filings since 18 October 2025.
All open-market trades in the period are sales: 10 sales worth €437k, by 1 insider, with no purchase on record. The largest single trade was a sale of €76k by Francisco Trust under agreement dated February 28, 1996, published on 6 July 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 18 filings in twelve months, the company is quieter than the median of 19 filings across the 5,816 companies we follow on the same exchange. Our records for Dyadic International Inc go back to 2021, with 3 purchases and 15 sales on the open market in total.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
58
Thresholds
n/a
Buy Volume
€74,113
3 ops. · all time
Sell Volume
€1M
15 ops. · all time
Who traded when
BuySaleFrancisco Trust under agreement dated February 28, 19969 sales
Joseph P. Hazelton1 buy
Since the insiders bought
- +3.0%Entry US$0.99 · Close at T+365 US$1.02
- -37.0%Entry US$3.92 · Close at T+365 US$2.47
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.42
Analyst consensus
2 analysts1.00/5
US$4.00Target US$5.50(+1211%)US$7.00
Income statement
RevenueUS$1.2M
Gross profit-US$1.1M-88% margin
EBITDA-US$6.9M-561% margin
Net income-US$7.4M-200.5% margin
Valuation
Beta0.96
Balance sheet & cash
Market capUS$16.8M
Total debtUS$5.1M
Free Cash Flow-US$5.7M
Profitability & ownership
ROE-2826.9%
ROA-63.0%
% insiders22.9%
% institutions12.5%
Last declaration on 24 July 2026
Declarations58 total
2,616 shares@ US$1.21310.019% mcap0.5% of flowCommon StockSEC:0001493152-26-034613:2
38,016 shares@ US$1.32790.30% mcap7.6% of flowCommon StockSEC:0001493152-26-034613:0
54,760 shares@ US$1.30210.43% mcap10.7% of flowCommon StockSEC:0001493152-26-034613:1
364,387 shares@ US$1.483.23% mcap81.2% of flowCommonSEC144:0001493152-26-034116
20,000 shares@ US$1.92299.0% of flowCommon StockSEC:0001493152-26-032062:5
41,143 shares@ US$1.836717.4% of flowCommon StockSEC:0001493152-26-032062:2
40,000 shares@ US$1.976818.2% of flowCommon StockSEC:0001493152-26-032062:4
26,340 shares@ US$2.426414.1% of flowCommon StockSEC:0001493152-26-032062:0
25,281 shares@ US$1.872511.0% of flowCommon StockSEC:0001493152-26-032062:1
5,100 shares@ US$1.80242.1% of flowCommon StockSEC:0001493152-26-032062:3
15,000 shares@ US$2.01497.0% of flowCommon StockSEC:0001493152-26-032062:6
18,064 shares0Common StockSEC:0001493152-26-000664:0
36,418 shares0Common StockSEC:0001493152-26-000654:0
102,609 shares0Common StockSEC:0001493152-26-000653:0
29,158 shares0Common StockSEC:0001493152-26-000663:0
21,552 sharesCommon StockSEC:0001493152-26-000662:0
21,552 sharesCommon StockSEC:0001493152-26-000657:0
26,000 shares@ US$0.9522.6% of flowCommon StockSEC:0001641172-25-022280:0
Canonical exit: 30 Oct 2025 (T+90)
10,776 sharesCommon StockSEC:0001437749-25-021100:0
10,776 sharesCommon StockSEC:0001437749-25-021101:0
18,750 shares@ US$0.9739.4% of flowCommon StockSEC:0001437749-25-000761:0
30,172 shares0Common StockSEC:0001437749-25-000547:0
20,776 shares0Common StockSEC:0001437749-25-000549:0
25 of 58 declarations
About Dyadic International Inc
Dyadic International, Inc. (NASDAQ: DYAI) is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States, with headquarters in Jupiter, Florida. For investors, the name sits at the intersection of industrial biotechnology, life-science inputs, and precision fermentation rather than traditional pharmaceutical development. The company traces its roots back to the 1980s, when it began developing industrial enzymes, and its technology base accelerated in the 1990s with the discovery of its proprietary fungal host, Thermothelomyces heterothallica. In 2025, the company broadened its branding to “Dyadic Applied BioSolutions,” signaling a shift from a legacy enzyme story toward a wider applied-biotech platform.
Dyadic’s business model centers on two microbial expression platforms, C1 and Dapibus™, which are designed to produce recombinant proteins and enzymes at scale with a cost and speed profile the company believes can compete favorably with legacy systems. The platforms are intended to support non-therapeutic, high-value input proteins for life sciences, food and nutrition, and industrial biotechnology. In practical terms, Dyadic is targeting applications such as cell-culture media ingredients, diagnostics, bioprocessing aids, nutritional proteins, and enzyme solutions for industrial and food use. Key product and program areas include recombinant serum albumin, transferrin, DNase I, growth factors, nucleic-acid enzymes, and non-animal ingredients for the food and nutrition sector.
Read moreShow less
From a competitive perspective, Dyadic remains a niche player relative to large enzyme, fermentation, and biosolutions companies. Its differentiation comes from its proprietary IP, its fungal expression platform, and its ability to turn platform validation into commercial agreements. Rather than relying solely on internal product launches, the company is pursuing a partner-led strategy with names such as Proliant, Fermbox Bio, IBT Bioservices, BRIG Bio, and Inzymes. These relationships are important because they can expand market access, reduce commercialization friction, and create multiple revenue streams through licensing, milestone payments, and potential royalties.
Geographically, Dyadic is a United States company, but its commercial footprint is increasingly international through manufacturing, licensing, and distribution partners. Recent developments have been especially notable in 2025 and early 2026. The company reported progress in moving from R&D toward commercialization, including the launch of AlbuFree™ DX with Proliant, an OEM distribution agreement with IBT Bioservices, continued collaboration with Fermbox Bio, and advancement of nutrition-focused programs such as animal-free alpha-lactalbumin. It also highlighted ongoing work on Gates Foundation-supported RSV and malaria antibody programs, plus CEPI/FBS-supported H5 avian influenza efforts. Overall, Dyadic remains an early-stage, commercialization-focused biotech with meaningful optionality, but also execution risk typical of small-cap platform companies.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
